Open AccessLosartan-induced ischemic hepatocellular hepatotoxicity: A case report and literature review
Author(s) -
Moh’d Al-Halawani,
Mohammad Thawabi,
Fady Asslo,
Hamid Shaaban,
Fayez Shamoon,
Walid Baddoura
Publication year - 2014
Publication title -
journal of family medicine and primary care
Language(s) - English
Resource type - Journals
eISSN - 2278-7135
pISSN - 2249-4863
DOI - 10.4103/2249-4863.141635
Subject(s) - medicine , losartan , angiotensin ii receptor type 1 , adverse effect , incidence (geometry) , angiotensin ii , cardiology , pharmacology , blood pressure , physics , optics
With the increasing use of various medications and supplements nowadays, the incidence of abnormal liver function tests and frank hepatic injury is has been increasing. Medications are now considered one of the most common causes of acute hepatic failure in the United States. Losartan was the first angiotensin 1 (AT1) receptor blocker approved by FDA for the treatment of arterial hypertension. It is a well-tolerated medication with few significant adverse effects. However, losartan-related hepatotoxicity has been reported rarely. We report a case of acute hepatic injury in an adult patient treated with losartan as a monotherapy for arterial hypertension.